Identification of pathway-selective estrogen receptor ligands that inhibit NF-κB transcriptional activity
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Inflammation is now recognized as a key component in a number of diseases such as atherosclerosis, rheumatoid arthritis, and inflammatory bowel disease. The transcription factor NF-κB has been shown to be involved in both the early and late stages of the inflammatory-proliferative process. In this report, we describe the identification of the pathway-selective estrogen receptor (ER) ligand, WAY-169916, that inhibits NF-κB transcriptional activity but is devoid of conventional estrogenic activity. This pathway-selective ligand does not promote the classic actions of estrogens such as stimulation of uterine proliferation or ER-mediated gene expression, but is a potent antiinflammatory agent, as demonstrated in the HLA-B27 transgenic rat model of inflammatory bowel disease. Our results indicate the potential utility of pathway-selective ER ligands such as WAY-169916 in the treatment of chronic inflammatory diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kuiper, G. G. J. M., Carlsson, B., Grandien, K., Enmark, E., Häggblad, J., Nilsson, S., & Gustafsson, J.-A. (1997) · Endocrinology · doi:10.1210/endo.138.3.4979 · Cited by 4,442
NF-κB: a key role in inflammatory diseases
Tak, P. P., & Firestein, G. S. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11830 · Cited by 3,918
Activators and target genes of Rel/NF-κB transcription factors
Pahl, H. L. (1999) · Oncogene · doi:10.1038/sj.onc.1203239 · Cited by 3,727
Schäcke, H., Schottelius, A., Döcke, W.-D., Strehlke, P., Jaroch, S., Schmees, N., Rehwinkel, H., Hennekes, H., & Asadullah, K. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0300372101 · Cited by 466
Reversal of Bone Loss in Mice by Nongenotropic Signaling of Sex Steroids
Kousteni, S., Chen, J.-R., Bellido, T., Han, L., Ali, A. A., O'Brien, C. A., Plotkin, L., Fu, Q., Mancino, A. T., Wen, Y., et al. (2002) · Science · doi:10.1126/science.1074935 · Cited by 420
Harris, H. A., Katzenellenbogen, J. A., & Katzenellenbogen, B. S. (2002) · Endocrinology · doi:10.1210/en.2002-220403 · Cited by 357
Self-citationEstrogen receptors in mast cells from arterial walls
NICOVANI, S., & RUDOLPH, M. I. (2002) · BIOCELL · doi:10.32604/biocell.2002.26.015 · Cited by 27
Cited by
The complex role of estrogens in inflammation
Straub, R. H. (2007) · Endocrine Reviews · doi:10.1210/er.2007-0001 · Cited by 1,950
Aryl hydrocarbon receptor ligands in cancer: friend and foe
Murray, I. A., Patterson, A. D., & Perdew, G. H. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3846 · Cited by 883
The Aryl Hydrocarbon Receptor Complex and the Control of Gene Expression
Beischlag, T. V., Morales, J. L., Hollingshead, B. D., & Perdew, G. H. (2008) · Critical Reviews™ in Eukaryotic Gene Expression · doi:10.1615/critreveukargeneexpr.v18.i3.20 · Cited by 727
International Union of Pharmacology. LXIV. Estrogen Receptors
Dahlman-Wright, K., Cavailles, V., Fuqua, S. A., Jordan, V. C., Katzenellenbogen, J. A., Korach, K. S., Maggi, A., Muramatsu, M., Parker, M. G., & Gustafsson, J.-Å. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.4.8 · Cited by 583
“…studies show a protective effect of estrogens on multiple sclerosis (Soldan et al., 2003; Alonso et al., 2005), most likely due to the immunomodulatory and anti-inflammatory effects of estrogens reported by several laboratories (Cuzzocrea et al., 2000; Liu et al., 2003; Chadwick et al., 2005).”
BackgroundShanle, E. K., & Xu, W. (2011) · Chemical Research in Toxicology · doi:10.1021/tx100231n · Cited by 522
Central effects of estradiol in the regulation of food intake, body weight, and adiposity
Brown, L. M., & Clegg, D. J. (2010) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2009.12.005 · Cited by 331
Sexual Dimorphism in Innate Immunity: The Role of Sex Hormones and Epigenetics
Shepherd, R., Cheung, A. S., Pang, K., Saffery, R., & Novakovic, B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.604000 · Cited by 304
Turgeon, J. L., Carr, M. C., Maki, P. M., Mendelsohn, M. E., & Wise, P. M. (2006) · Endocrine Reviews · doi:10.1210/er.2005-0020 · Cited by 264
Robinson, D. P., Lorenzo, M. E., Jian, W., & Klein, S. L. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002149 · Cited by 256
Cross-talk between nuclear receptors and nuclear factor κB
De Bosscher, K., Vanden Berghe, W., & Haegeman, G. (2006) · Oncogene · doi:10.1038/sj.onc.1209935 · Cited by 247
“…block NF-kB signaling through binding to either ERa or ERb, but fails to induce classical ER-mediated target gene effects, suggesting that such compounds could be valuable for the treatment of ER-positive breast cancers where inhibition of NF-kB can induce apoptosis (Chadwick et al., 2005).”
BackgroundMechanisms of sex disparities in influenza pathogenesis
Klein, S. L., Hodgson, A., & Robinson, D. P. (2012) · Journal of Leukocyte Biology · doi:10.1189/jlb.0811427 · Cited by 219
“High E2 has potent anti-inflammatory actions, including repression of proinflammatory gene transcription and cytokine production [6, 43], which is partially mediated by inhibition of NF- B transcriptional activity [44].”
BackgroundNFκB selectivity of estrogen receptor ligands revealed by comparative crystallographic analyses
Nettles, K. W., Bruning, J. B., Gil, G., Nowak, J., Sharma, S. K., Hahm, J. B., Kulp, K., Hochberg, R. B., Zhou, H., Katzenellenbogen, J. A., et al. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.76 · Cited by 159
Wu, W.-F., Tan, X.-J., Dai, Y.-B., Krishnan, V., Warner, M., & Gustafsson, J.-Å. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1300313110 · Cited by 149
Coupling of receptor conformation and ligand orientation determine graded activity
Bruning, J. B., Parent, A. A., Gil, G., Zhao, M., Nowak, J., Pace, M. C., Smith, C. L., Afonine, P. V., Adams, P. D., Katzenellenbogen, J. A., et al. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.451 · Cited by 142
“Results Characterization of WAY-169916–driven ER activities The ERα partial agonist ligand WAY-169916 ( Table 1 ) represents the first example of an ER ligand that has broad anti-inflammatory activity in vivo but lacks the proliferative effects associated with strong transcriptional activatio”
BackgroundSex and gender differences in myocarditis and dilated cardiomyopathy: An update
Fairweather, D., Beetler, D. J., Musigk, N., Heidecker, B., Lyle, M. A., Cooper, L. T., & Bruno, K. A. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1129348 · Cited by 124
Metadata
- Authors
- Chadwick, C. C., Chippari, S., Matelan, E., Borges-Marcucci, L., Eckert, A. M., Keith, J. C., Albert, L. M., Leathurby, Y., Harris, H. A., Bhat, R. A., Ashwell, M., Trybulski, E., Winneker, R. C., Adelman, S. J., Steffan, R. J., & Harnish, D. C.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2005-02-07
- Volume
- 102
- Issue
- 7
- Pages
- 2543-2548
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2071535433
- Cited by
- 137
- References
- 7
- FWCI
- 8.57
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.